| Date | Title | Description |
| 04.01.2024 | Alex Therapeutics Reports Positive Results from the Randomized-Controlled Trial | Alex Therapeutics and Vicore Pharma today announced positive results of the COMPANION study, investigating the efficacy of Almee, a 9-week digital CBT intervention accessed through a smartphone or tablet. The study met its primary endpoint,... |
| 21.12.2023 | Hadean Ventures announces oversubscribed final close of Hadean Capital II | Hadean Ventures announces oversubscribed final close of Hadean Capital II – a fund dedicated to investments in life science start-ups across Europe
Oslo, 21 December 2023. Hadean Ventures announced today the final close of Hadean Capital I... |
| 08.12.2023 | Ribbon Biolabs appoints Jodi Barrientos Chief Executive Officer | Ribbon Biolabs appoints Jodi Barrientos Chief Executive Officer; Founder Harold De Vladar named an advisor and board member.
Vienna, Austria, December 6, 2023 – Ribbon Biolabs GmbH, the DNA synthesis company, announced today that its Board... |
| 09.11.2023 | Complement Therapeutics Enrols First US Participant | Complement Therapeutics Enrols First US Participant in the Non-interventional i-GAIN Study of People Diagnosed with Geographic Atrophy
Munich, Germany – 9th November 2023 – Complement Therapeutics GmbH (CTx), a preclinical stage biotechnol... |
| 13.10.2023 | Abliva Achieves Important Milestone in the Ongoing FALCON Study | Abliva AB (Nasdaq Stockholm: ABLI) a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that the company has now included the target number of patients required for sc... |
| 05.09.2023 | Abliva’s Lead Candidate KL1333 Receives FDA Fast Track Designation | Abliva’s Lead Candidate KL1333 Receives FDA Fast Track Designation
Abliva AB (Nasdaq Stockholm: ABLI) a clinical-stage company developing drugs for the
treatment of rare and severe primary mitochondrial disease, today announced that the
... |
| 03.05.2023 | ARTHEx Biotech Announces Closing of €42 M Series B Financing | ARTHEx Biotech Announces Closing of €42 M Series B Financing to Advance ATX-01, its Novel Treatment for Myotonic Dystrophy Type 1 (DM1)
The ArthemiRTM trial, a Phase I-IIa study of ATX-01 in DM1, is expected to initiate in 2H2023
Round le... |
| 17.04.2023 | Complement Therapeutics Secures €72 Million in Series A Financing | Complement Therapeutics Secures €72 Million in Series A Financing
to Advance Novel Therapies Targeting Complement-Mediated
Diseases
• Round led by Gimv, a Belgian based private equity and venture capital firm
• Round comes just 1 year a... |
| 05.03.2023 | Alex Therapeutics extends financing round to €4.75M with leading life science VC | Innovestor Life Science, a leading biotech and digital health VC, invests €1.25M in the digital therapeutics (DTx) company Alex Therapeutics. With this extension, the company has secured a total of €4.75M this round. Innovestor joins an imp... |
| 06.12.2022 | Alex Therapeutics and Vicore Pharma today announce the first study subject enrolled in the pivotal study COMPANION evaluating Almee™ | - |
| 24.10.2022 | Step Pharma Announces First Patient Dosed with STP938, the World’s Most Advanced CTPS1 Inhibitor, in a Phase 1/2 Trial for T cell and B cell lymphomas | Step Pharma Announces First Patient Dosed with STP938, the World’s Most
Advanced CTPS1 Inhibitor, in a Phase 1/2 Trial for T cell and B cell lymphomas
• Potential first-in-class targeted treatment for relapsed/refractory T cell and B cell... |
| 21.10.2022 | Gesynta Pharma prepares Phase II study of GS-248 in endometriosis following ground-breaking data from a preclinical proof-of-concept study | 20 October, 2022
Stockholm, Sweden, October 20, 2022 – Gesynta Pharma AB today announces the decision to advance the development of its clinical-stage drug candidate GS-248 in endometriosis – a chronic inflammatory condition affecting appr... |
| 14.10.2022 | Alex Therapeutics presents results from digital therapeutic pilot study showing nearly 50% reduction in anxiety | - |
| 27.07.2022 | Cardior Announces First Patient Dosed in Phase 2 Study | Hanover, Germany, July 20, 2022 – Cardior Pharmaceuticals, a clinical-stage biotech
company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac
diseases, today announced the dosing of the first patient in their ... |
| 15.07.2022 | Gesynta Pharma completes patient enrollment in its Phase II study in systemic sclerosis | Stockholm, Sweden, 12 July 2022 –
Gesynta Pharma AB today announces that all patients have
been recruited for the company’s clinical Phase II study with the drug candidate GS-248, which is
being evaluated as a treatment for the rare diso... |
| 03.07.2022 | Attgeno AB announces fully subscribed share issue to complete clinical phase II study in acute pulmonary hypertension | Attgeno AB announces that a successful share issue was completed at midsummer 2022 and resulted in SEK 20 million to a valuation of SEK 378 million after the issue. The issue consists of SEK 15 million in a rights issue to existing owners a... |
| 30.06.2022 | Vi søker jurist! | Om stillingen
Vi har behov for å styrke vår interne juridiske kompetanse. Som advokat/jurist i Hadean får du anledning til å utvikle god kompetanse innen finans- og verdipapirrett, compliance, samt problemstillinger knyttet til et internas... |
| 02.06.2022 | Attgeno announces approval of initiation of Phase 2 clinical trial of Supernitro in patients with acute pulmonary hypertension | Attgeno AB today announced that it has received approval from the Swedish Medical Products Agency and the Swedish Ethical Review Authority to start a phase 2 clinical trial of its lead drug candidate Supernitro as a potentially lifesaving t... |
| 01.06.2022 | Abliva decides on a SEK 200 million financing to fund Phase 2/3 study of KL1333 to interim analysis and bring in new global life science and institutional investors
| - |
| 27.04.2022 | Gesynta Pharma’s drug candidate GS-248 granted Orphan Drug Designation by the FDA | Gesynta Pharma’s drug candidate GS-248 granted Orphan Drug Designation in
US by the FDA for the treatment of systemic sclerosis
Stockholm, Sweden, 27 April 2022 – Gesynta Pharma AB today announces that the U.S. Food and
Drug Administrati... |
| 06.04.2022 | Alex Therapeutics raises €3.5M in oversubscribed financing round |
STOCKHOLM, April 6, 2022 /PRNewswire/ — Stockholm-based Digital Therapeutics (DTx) company Alex Therapeutics today announces it has secured a €3.5M funding round, led by European life science venture fund Hadean Ventures and joined by Sca... |
| 22.02.2022 | TargED Biopharmaceuticals raises EUR 39 Million in Series A financing | TargED Biopharmaceuticals raises EUR 39 Million in Series A financing to bring
groundbreaking thrombolytic treatment to patients
• Financing with equal contribution by an international investor syndicate comprising of Andera
Partners, Fu... |
| 31.01.2022 | Ribbon Biolabs raises EUR 18 million in its Series A financing | VIENNA, AUSTRIA, January 31, 2022 —
Ribbon Biolabs, the DNA synthesis company, today
announced the successful close of EUR 18 million in its Series A funding round from a
consortium of European and US investors led by Hadean Ventures and... |
| 10.12.2021 | Emergence Therapeutics raises €87 million Series A financing to advance Nectin-4 ADC | Duisburg, Germany, 7 December 2021. Emergence Therapeutics AG, a biopharmaceutical company developing novel antibody drug conjugates (ADC) for the treatment of cancers with high unmet needs, today announces that it has closed an €87 million... |
| 27.09.2021 | Hadean Ventures Announces the 1st Closing of EUR 90m for its Second Fund | - |
| 26.08.2021 | Cardior Raises €64 M Series B to Advance Clinical Pipeline of RNA Therapeutics to Treat Cardiac Disease | Oversubscribed round enables late-stage clinical development of lead
candidate, a micro-RNA-132 inhibitor, in heart failure and further accelerates
pipeline expansion
Hanover, Germany, August 25, 2021 – Cardior Pharmaceuticals, a clinica... |
| 08.07.2021 | Attgeno appoints Björn Westberg as CFO | Attgeno AB announces today that Björn Westberg has been appointed CFO
and member of the management team at Attgeno. Björn most recently comes
from a role as CFO at Enea AB (publ).
Björn has extensive experience in the Life Science sector... |
| 29.06.2021 | Oncoinvent Secures NOK 250 M in an oversubscribed Pre-IPO Funding Round | Norwegian radiopharmaceutical company announces successful closing of a
private placement that will allow the company to initiate the next phase of
clinical development of its lead product candidate Radspherin®
Norway Oncoinvent AS, a cl... |
| 29.06.2021 | SAGA Diagnostics raises €10.5 million | SAGA Diagnostics raises SEK 106 million (€10.5 million) to accelerate commercialization of ultrasensitive cancer liquid biopsies
SAGA Diagnostics AB (“SAGA”), a cancer liquid biopsy and genomic testing company, today announced that it has ... |
| 15.06.2021 | Gesynta Pharma announces significant progress across development program for first-in-class drug candidate GS-248 | Stockholm, Sweden, June 14 2021
Gesynta Pharma announces significant progress across development program for first-in-class drug candidate GS-248IND submitted for systemic sclerosis and 50% recruitment milestone in Phase II study reached.
... |
| 19.05.2021 | Abliva reports positive clinical Phase 1a/b results for KL1333 including signs of efficacy in PMD patients | Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases (PMD), today announced positive safety and pharmacokinetic data from the... |
| 30.04.2021 | Join Hadean Ventures! |
April 30, 2021
Hadean Ventures is a fast-growing life science fund manager that invests in companies across Europe and beyond with a particular focus on the Nordic region. We invest into leading companies that have the potential to shape... |
| 09.04.2021 | Safety Monitoring Committee Approves 7 MBq as Recommended Clinical Dose for Radspherin® | 7MBq dose of Radspherin® determined to be safe, and approved by the SMC as the recommended clinical dose for repeated injection and expansion cohorts of RAD-18-002 study
Oncoinvent AS, a clinical stage company advancing a pipeline of radio... |
| 24.03.2021 | Step Pharma Raises EUR35 Million in Series B Financing to Advance First in Class CTPS1 inhibitor into the Clinic in T Cell Malignancies | Archamps, France, 24 March 2021
Step Pharma, a biotech company developing novel drugs for oncology and autoimmune diseases, today announced the successful closing of a EUR35 million Series B financing. New investors Hadean Ventures and Sun... |
| 11.03.2021 | Oncoinvent Announces Progression of Radspherin® to Third Dose Level Cohort in Ongoing RAD-18-001 Phase 1 Trial | Oncoinvent Announces Progression of Radspherin® to Third Dose Level Cohort in Ongoing RAD-18-001 Phase 1 Trial in Platinum Sensitive Recurrent Ovarian Cancer Patients with Peritoneal Carcinomatosis |
| 11.02.2021 | Pipeline Therapeutics Completes $80 Million Series C Financing | Pipeline Therapeutics – News – 02/11/2021 |
| 05.02.2021 | Ekspertenes biotekfavoritter i urolige tider, e24.no | Etter snart ett år med børsoppgang, er det flere eksperter som spekulerer om vi står foran mer urolige tider eller en korreksjon på Oslo Børs.En sektor som ofte trekkes frem når markedet er usikkert, er helse- og bioteknologiaksjene.
Uanse... |
| 26.01.2021 | Gesynta Pharma initiates Phase II study of its first-in-class drug candidate GS- 248 in patients with systemic sclerosis | Stockholm, Sweden, January 26, 2020 –
Gesynta Pharma AB today announced that the first
patients have been dosed in a Phase II study of its oral drug candidate GS-248 in patients with
systemic sclerosis – a debilitating autoimmune disease... |
| 21.01.2021 | Abliva appoints Ellen Donnelly as new CEO as they enter a new development stage | Abliva appoints Ellen Donnelly as new CEO as it enters a new stage in its development – Abliva |
| 11.01.2021 | Oncoinvent Announces Advancement of Radspherin® to Final Dose Level Cohort in Ongoing RAD-18-002 Phase 1 Trial in Colorectal Cancer Patients | Safety Monitoring Committee review of third dose-level cohort allows progression of Phase 1 RAD-18-002 study to fourth and final cohort dose level cohort
Oslo 11, January 2020
Oncoinvent AS, a clinical stage company advancing a pipeline o... |
| 03.01.2021 | Helsestartups får stryk på mangfold, e24.no | Helsestartups får stryk på mangfold – E24 av: Ina Vedde-Fjærestad |
| 01.12.2020 | Galecto Publishes GB0139 Phase 2a (IPF) Results in European Respiratory Journal | BOSTON and COPENHAGEN, Denmark, Nov. 30, 2020 (GLOBE NEWSWIRE) — Galecto, Inc., a NASDAQ listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, announced today the publication of a paper detaili... |
| 17.11.2020 | Abliva receives positive regulatory feedback from UK MHRA on KL1333 Phase II/III study plan | Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announced it has received positive feedback from the UK Medicines... |
| 10.11.2020 | Abliva initiates a drug-drug interaction study and paves the way for a KL1333 pivotal study in 2021 | Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announces dosing in the first healthy volunteers in the company’s... |
| 29.10.2020 | Oncoinvent Advances Radspherin® to Third Dose Level in Ongoing Phase 1 Clinical Trial | Safety review of second dose-level cohort allows study to advance to third cohort of colorectal cancer patients with peritoneal carcinomatosis in Radspherin® clinical trial.
Oncoinvent AS, a clinical stage radiopharmaceutical company devel... |
| 28.10.2020 | Galecto Announces Pricing of Initial Public Offering | BOSTON and COPENHAGEN, Denmark, Oct. 28, 2020 (GLOBE NEWSWIRE) — Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company developing therapeutics that are designed to target the biological processes that lie at the heart of fibr... |
| 22.10.2020 | Neuro Event Labs Receives FDA Breakthrough Device Designation for Nelli® | SAN ANTONIO (PRWEB) OCTOBER 22, 2020
Neuro Event Labs, Inc., a global diagnostic company, announced that Nelli® received a Breakthrough Device designation from the U.S. Food and Drug Administration (FDA). The system is designed to automate... |
| 08.10.2020 | Abliva doses the first patient in its KL1333 Phase Ia/b clinical study | Abliva AB (Nasdaq Stockholm: ABLI) today announced that the first primary mitochondrial disease patient in the company’s ongoing KL1333 Phase Ia/b study has been dosed. In this third part of the study, the pharmaceutical properties of KL133... |
| 25.09.2020 | Hadean Ventures invest in Galecto`s $64 million round equity financing |
BOSTON and COPENHAGEN, Denmark, Sept. 25, 2020 (GLOBE NEWSWIRE) — Galecto, Inc., a privately-held biotechnology company focused on the development of novel treatments for fibrosis and cancer, announced today the successful completion of a... |
| 14.09.2020 | Ingrid Teigland Akay included in Business Insider’s list of 100 People Transforming Business in Europe. | - |
| 09.09.2020 | Abliva intends to start a pivotal KL1333 study second half 2021 | - |
| 04.09.2020 | Oncoinvent Advances Radspherin[®] to Second Dose Level in Ongoing Phase 1 Clinical Trial | FRI, SEP 04, 2020 09:19 CET
Safety review of first dose-level cohort allows progression to second cohort of colorectal cancer patients with peritoneal carcinomatosis in Radspherin® clinical trial.
Oslo 4. September 2020
Oncoinvent AS, a ... |
| 14.08.2020 | Pewin Member Highlight 2020: Ingrid Teigland Akay | - |
| 06.08.2020 | CardioMech AS Announces $18.5M Series A for its Transcatheter Mitral Valve Repair Technology | The Series A, led by a non-disclosed strategic investor, together with Hadean Ventures and Investinor, will fund CardioMech’s journey to treat patients in a first-in-human feasibility trial
MINNEAPOLIS, Aug. 5, 2020 /PRNewswire/ — Minneapo... |
| 28.07.2020 | Gesynta raises SEK 190 million in round led by Hadean Ventures to accelerate development of first-in-class mPGES-1 inhibitor GS-248 for systemic sclerosis | July 7, 2020, Stockholm |
| 28.07.2020 | Pipeline Therapeutics Initiates Phase 1/2a Clinical Trial of PIPE-505 in Sensorineural Hearing Loss | SAN DIEGO, July 23, 2020 – Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the initiation of a Phase 1/2a trial of ... |
| 28.07.2020 | Abliva receives positive FDA feedback on its KL1333 development plan | - |
| 18.06.2020 | €1.9M EU funding takes Nelli® available for all epilepsy patients | Neuro Event Labs (NEL) will use €1.9M EU Horizon 2020 grant to become the standard of care in epilepsy diagnostics. The competitive EU Horizon 2020 grant was only awarded to 1,4% of applicants. The jury highlighted the novelty, clear unmet ... |
| 15.06.2020 | Abliva completes the directed issue of MSEK 20 to Hadean Ventures | On April 22, 2020, the Board of Directors of Abliva AB (publ) (“Abliva” or the “Company”) resolved, supported by the authorization granted at the Annual General Meeting on April 25, 2019, on a directed issue of up to 27,892,888 shares (the ... |
| 11.06.2020 | Oncoinvent Announces Dosing of First Patient with Radspherin® in a Second Phase 1 Clinical Trial | Radiopharmaceutical company starts first-in-human trial in a second patient population; ovarian cancer patients suffering from peritoneal carcinomatosis
Oncoinvent AS, a clinical stage radiopharmaceutical company developing novel radioisot... |
| 02.06.2020 | Oncoinvent Announces Dosing of First Patient with Radspherin® in Phase 1 Clinical Trial | Press Release 02.2020: Radiopharmaceutical company starts first-in-human trial in colorectal patients suffering from peritoneal carcinomatosis
Oncoinvent AS, a clinical stage radiopharmaceutical company developing novel radioisotope-based ... |
| 26.05.2020 | MSD to Acquire Themis | Merck to Apply its Industry-Leading Vaccine Development Capabilities to SARS-CoV-2 Vaccine Program Originated by Themis and Institut Pasteur
KENILWORTH, N.J.–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside the United States and Ca... |
| 22.04.2020 | NeuroVive makes a MSEK 20 directed share issue to leading Nordic life science investor Hadean Ventures | NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (”NeuroVive” or the ”Company”) has today decided upon a directed issue of shares totaling around MSEK 20 to Hadean Ventures (“Directed Issue”). Hadean Ventures has undertaken, on certain c... |
| 16.04.2020 | Varsler massive coronakjøp, Finansavisen | - |
| 09.04.2020 | Neuro Event Labs Oy closes EUR 3.9m Series A investment round from Hadean Ventures, SHS Gesellschaft für Beteiligungsmanagement and Maki.vc | - |
| 20.03.2020 | Themis and Institut Pasteur Join Coronavirus Vaccine Hunt | The Austrian biotech Themis — specializing in vaccines for infectious and insect-borne diseases — has jumped on the coronavirus vaccine bandwagon along with the Institut Pasteur and other international partners.
The collaboration will be l... |
| 18.12.2019 | Pipeline Therapeutics Completes $30 Million Series B Financing | - |
| 27.11.2019 | Hadean Ventures receives Rising Star Award at the 10th edition of the Private Equity Exchange & Awards 2019 in Paris | Paris – Today Hadean Ventures won the Rising Star Award at the 10th edition of the Private Equity Exchange & Awards 2019 in Paris.
“It is a great honour to receive this prize today. It is an acknowledgment of our team’s combined effort... |
| 18.09.2019 | Hadean Ventures invests in Themis Bioscience GmbH EUR 40m Series D Financing round | - |
| 11.06.2019 | Hadean Ventures leads 40 million SEK (€3.7 million) investment round into SAGA to advance ultrasensitive cancer liquid biopsies | LUND, Sweden and OSLO, Norway, June 11, 2019 — /B3C Newswire/ — SAGA Diagnostics AB, a precision oncology genomics testing company focused on ultrasensitive monitoring of cancer patients using blood samples and other liquid biopsies and tis... |
| 26.03.2019 | Level 20 selects Ingrid Teigland Akay as one of nine Inspiring Women in European Private Equity |
8th March 2019. In connection with the International Women’s Day, Level 20 released nine profiles of Inspiring Women in European private equity, amongst those Hadean Ventures founder and managing partner, Ingrid Teigland Akay.
Level 20 i... |
| 26.03.2019 | Hadean Ventures’ Ingrid Teigland Akay receives Investor of the Year award at the SHE conference | Oslo 6th March, 2019. Today Ingrid Teigland Akay, founder and managing partner at Hadean Ventures, received the Investor of the Year award at the SHE conference 2019.
The SHE conference is Europe’s largest gender diversity conference held ... |
| 06.11.2018 | Hadean Ventures is pleased to announce the appointment of Roger Franklin PhD as Partner to be based in Hadean’s Stockholm office at the Karolinska Institute Science Park. |
Stockholm 01.11.2018. Hadean Ventures is pleased to announce the appointment of Roger Franklin PhD as Partner to be based in Hadean’s Stockholm office at the Karolinska Institute Science Park. Roger has over a decade of experience in the ... |
| 13.07.2018 | Hadean Ventures, SINTEF Venture V and Investinor invest in Nisonic AS to develop advanced ultrasound technology for neurological conditions. | 13th July 2018, Oslo, Stockholm, Trondheim. Hadean Ventures today announced an investment in Nisonic AS, a Trondheim, Norway, based medtech company originating from SINTEF, one of Europe’s largest independent research organizations. The NOK... |
| 16.06.2018 | Investorview: Plugging knowledge gaps to accelerate life science start-up development | Investorview – Hadean Ventures 010618 |
| 22.05.2018 | Hadean Ventures today announces an investment in AttgeNO AB, a Swedish pharmaceutical company developing treatments for acute life-threatening conditions. | 22nd May 2018, Stockholm, Oslo. Hadean Ventures today announces an investment in AttgeNO AB, a Swedish pharmaceutical company developing treatments for acute life-threatening conditions. The lead candidate Supernitro (PDNO) is targeting acu... |
| 18.12.2017 | Hadean Ventures launches new fund to leverage untapped potential of European life science startups | 18.12.2017, Oslo, Stockholm – Hadean Ventures announced today the closing of Hadean Capital I, a
new fund with a target size of €100 million that will invest in life science companies. A particular
attention will be given to regions of Eu... |
